FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116395845> ?p ?o ?g. }

• W2116395845 abstract "Background Poorly controlled asthma and preventable exacerbations place a significant strain on healthcare, often requiring additional medications, hospital stays or treatment in the emergency department. Long‐acting beta2‐agonists (LABA) are the preferred add‐on treatment for adults with asthma whose symptoms are not well controlled on inhaled corticosteroids (ICS), but have important safety concerns in asthma. Long‐acting muscarinic antagonists (LAMA) have confirmed efficacy in chronic obstructive pulmonary disease and are now being considered as an alternative add‐on therapy for people with uncontrolled asthma. Objectives To assess the efficacy and safety of adding a LAMA to ICS compared with adding a LABA for adults whose asthma is not well controlled on ICS alone. Search methods We searched the Cochrane Airways Group's Specialised Register (CAGR) from inception to April 2015, and imposed no restriction on language of publication. We searched additional resources to pick up unpublished studies, including ClinicalTrials.gov, World Health Organization trials portal, reference lists of primary studies and existing reviews, and manufacturers' trial registries. The most recent search was conducted in April 2015. Selection criteria We searched for parallel and cross‐over RCTs in which adults whose asthma was not well controlled with ICS alone were randomised to receive LAMA add‐on or LABA add‐on for at least 12 weeks. Data collection and analysis Two review authors independently screened the electronic and additional searches and extracted data from study reports. We used Covidence for duplicate screening, extraction of study characteristics and numerical data, and risk of bias ratings. The pre‐specified primary outcomes were exacerbations requiring oral corticosteroids (OCS), quality of life and serious adverse events. Main results We included eight studies meeting the inclusion criteria, but four double‐blind, double‐dummy studies of around 2000 people dominated the analyses. These four trials were between 14 and 24 weeks long, all comparing tiotropium (usually Respimat) with salmeterol on top of medium doses of ICS. Studies reporting exacerbations requiring OCS showed no difference between the two add‐ons, but our confidence in the effect was low due to inconsistency between studies and because the confidence intervals (CI) included significant benefit of either treatment (odds ratio (OR) 1.05, 95% CI 0.50 to 2.18; 1753 participants; 3 studies); three more people per 1000 might have an exacerbation on LAMA, but the CIs ranged from 29 fewer to 61 more. Imprecision was also an issue for serious adverse events and exacerbations requiring hospital admission, rated low (serious adverse events) and very low quality (exacerbations requiring hospital admission), because there were so few events in the analyses. People taking LAMA scored slightly worse on two scales measuring quality of life (Asthma Quality of Life Questionnaire; AQLQ) and asthma control (Asthma Control Questionnaire; ACQ); the evidence was rated high quality but the effects were small and unlikely to be clinically significant (AQLQ: mean difference (MD) ‐0.12, 95% CI ‐0.18 to ‐0.05; 1745 participants; 1745; 4 studies; ACQ: MD 0.06, 95% CI 0.00 to 0.13; 1483 participants; 3 studies). There was some evidence to support small benefits of LAMA over LABA on lung function, including on our pre‐specified preferred measure trough forced expiratory volume in one second (FEV1) (MD 0.05 L, 95% CI 0.01 to 0.09; 1745 participants, 4 studies). However, the effects on other measures varied, and it is not clear whether the magnitude of the differences were clinically significant. More people had adverse events on LAMA but the difference with LABA was not statistically significant. Authors' conclusions Direct evidence of LAMA versus LABA as add‐on therapy is currently limited to studies of less than six months comparing tiotropium (Respimat) to salmeterol, and we do not know how they compare in terms of exacerbations and serious adverse events. There was moderate quality evidence that LAMAs show small benefits over LABA on some measures of lung function, and high quality evidence that LABAs are slightly better for quality of life, but the differences were all small. Given the much larger evidence base for LABA versus placebo for people whose asthma is not well controlled on ICS, the current evidence is not strong enough to say that LAMA can be substituted for LABA as add‐on therapy. The results of this review, alongside pending results from related reviews assessing the use of LAMA in other clinical scenarios, will help to define the role of these drugs in asthma and it is important that they be updated as results from ongoing and planned trials emerge." @default.
• W2116395845 created "2016-06-24" @default.
• W2116395845 creator A5025906181 @default.
• W2116395845 creator A5042632065 @default.
• W2116395845 creator A5051660368 @default.
• W2116395845 creator A5057028908 @default.
• W2116395845 date "2015-06-02" @default.
• W2116395845 modified "2023-10-14" @default.
• W2116395845 title "Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta₂ -agonists (LABA) for adults with asthma" @default.
• W2116395845 cites W1482406435 @default.
• W2116395845 cites W1492735157 @default.
• W2116395845 cites W1501843833 @default.
• W2116395845 cites W1551457470 @default.
• W2116395845 cites W1593822197 @default.
• W2116395845 cites W1597616964 @default.
• W2116395845 cites W1626773437 @default.
• W2116395845 cites W1631769030 @default.
• W2116395845 cites W1793910073 @default.
• W2116395845 cites W1807048566 @default.
• W2116395845 cites W1858555081 @default.
• W2116395845 cites W1917912133 @default.
• W2116395845 cites W1930217537 @default.
• W2116395845 cites W194383558 @default.
• W2116395845 cites W1950302841 @default.
• W2116395845 cites W1962391690 @default.
• W2116395845 cites W2009191674 @default.
• W2116395845 cites W2020414852 @default.
• W2116395845 cites W2057557604 @default.
• W2116395845 cites W2078825058 @default.
• W2116395845 cites W2085457639 @default.
• W2116395845 cites W2093334569 @default.
• W2116395845 cites W2104692335 @default.
• W2116395845 cites W2105863984 @default.
• W2116395845 cites W2109613186 @default.
• W2116395845 cites W2111533388 @default.
• W2116395845 cites W2115817977 @default.
• W2116395845 cites W2116395845 @default.
• W2116395845 cites W2116899830 @default.
• W2116395845 cites W2117993701 @default.
• W2116395845 cites W2119147796 @default.
• W2116395845 cites W2126325768 @default.
• W2116395845 cites W2130235475 @default.
• W2116395845 cites W2146374592 @default.
• W2116395845 cites W2148583736 @default.
• W2116395845 cites W2152149480 @default.
• W2116395845 cites W2153441442 @default.
• W2116395845 cites W2159596326 @default.
• W2116395845 cites W2163441905 @default.
• W2116395845 cites W2165099891 @default.
• W2116395845 cites W2189580660 @default.
• W2116395845 cites W2298324399 @default.
• W2116395845 cites W2322037130 @default.
• W2116395845 cites W2330255005 @default.
• W2116395845 cites W2787113605 @default.
• W2116395845 cites W4205581585 @default.
• W2116395845 cites W4210418421 @default.
• W2116395845 cites W4236021574 @default.
• W2116395845 cites W4241241264 @default.
• W2116395845 cites W4241883193 @default.
• W2116395845 cites W4242285512 @default.
• W2116395845 cites W4253771981 @default.
• W2116395845 cites W4323254566 @default.
• W2116395845 doi "https://doi.org/10.1002/14651858.cd011438.pub2" @default.
• W2116395845 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6513433" @default.
• W2116395845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26031392" @default.
• W2116395845 hasPublicationYear "2015" @default.
• W2116395845 type Work @default.
• W2116395845 sameAs 2116395845 @default.
• W2116395845 citedByCount "21" @default.
• W2116395845 countsByYear W21163958452013 @default.
• W2116395845 countsByYear W21163958452015 @default.
• W2116395845 countsByYear W21163958452016 @default.
• W2116395845 countsByYear W21163958452017 @default.
• W2116395845 countsByYear W21163958452018 @default.
• W2116395845 countsByYear W21163958452019 @default.
• W2116395845 countsByYear W21163958452020 @default.
• W2116395845 countsByYear W21163958452021 @default.
• W2116395845 countsByYear W21163958452022 @default.
• W2116395845 countsByYear W21163958452023 @default.
• W2116395845 crossrefType "journal-article" @default.
• W2116395845 hasAuthorship W2116395845A5025906181 @default.
• W2116395845 hasAuthorship W2116395845A5042632065 @default.
• W2116395845 hasAuthorship W2116395845A5051660368 @default.
• W2116395845 hasAuthorship W2116395845A5057028908 @default.
• W2116395845 hasBestOaLocation W21163958452 @default.
• W2116395845 hasConcept C126322002 @default.
• W2116395845 hasConcept C168563851 @default.
• W2116395845 hasConcept C187212893 @default.
• W2116395845 hasConcept C2776042228 @default.
• W2116395845 hasConcept C2776780178 @default.
• W2116395845 hasConcept C2780911369 @default.
• W2116395845 hasConcept C2991922776 @default.
• W2116395845 hasConcept C71924100 @default.
• W2116395845 hasConceptScore W2116395845C126322002 @default.
• W2116395845 hasConceptScore W2116395845C168563851 @default.
• W2116395845 hasConceptScore W2116395845C187212893 @default.
• W2116395845 hasConceptScore W2116395845C2776042228 @default.
• W2116395845 hasConceptScore W2116395845C2776780178 @default.
• W2116395845 hasConceptScore W2116395845C2780911369 @default.
• W2116395845 hasConceptScore W2116395845C2991922776 @default.

• next